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H-Y minor histocompatibility antigens and the development of
chronic graft versus host disease (cGVHD) after allogeneic
hematopoietic stem cell transplantation (HSCT). These ﬁnd-
ings suggest that donor B cells play a role in the development of
cGVHD and clinical trials utilizing anti-CD20 monoclonal an-
tibody, rituximab, have demonstrated clinical improvement in
some patients with active resistant cGVHD. B cell activating
factor, BAFF, is a member of the TNF cytokine family that
binds to one of three cell surface receptors on B cells. Activation
of these B cell receptors by antigen and BAFF results in rapid
induction of proliferation and differentiation of germinal center
B cells into either Ig-secreting cells or memory B cells. The
ﬁnding that elevated BAFF levels in patients with autoimmune
diseases are associated with disease severity and autoantibody
production has led to clinical trials using anti-BAFF monoclonal
antibody in these diseases. To test whether BAFF contributes to
the activation of B cells in patients with cGVHD, we employed
a sandwich ELISA to measure soluble BAFF in plasma from 27
patients after allogeneic HSCT. Mean BAFF levels for extensive
(n  8), limited (n  8), resolved (n  6) or no (n  5) cGVHD
groups were: 7.3 ng/ml, 5.37 ng/ml, 3.92 ng/ml and 2.02 ng/ml,
respectively. The differences between the extensive or limited
groups versus the no cGVHD group were statistically signiﬁcant
(each P  .03) suggesting that BAFF levels corresponded with
cGVHD activity. B cell subsets in peripheral blood were also
examined by ﬂow cytometry to identify circulating memory B
cells. Of four cGVHD patients analyzed thus far, individuals
with active disease and high BAFF levels also had high numbers
of CD27 memory B cells in peripheral blood compared to
patients with resolved cGVHD and low BAFF levels. Ongoing
prospective, serial assessment of BAFF levels and B cell pheno-
type in larger numbers of patients will extend these results. We
propose that BAFF may serve as a new biomarker for cGVHD,
speciﬁcally identifying patients with active disease. If further
studies identify a pathologic role for increased BAFF in
cGVHD, anti-BAFF monoclonal antibodies may provide a new
therapeutic approach for this serious complication of allogeneic
HSCT.
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Bz-423 is a novel 1,4-benzodiazepine with both cytotoxic and
cytostatic effects on activated lymphocytes. Bz-423 has been
shown to suppress lupus in murine models by eliminating patho-
genic lymphocytes without altering normal immune function or
overt toxicities. We hypothesized that Bz-423 might enhance
the apoptotic deletion of alloreactive donor T cells and there-
fore reduce graft-versus-host disease (GVHD). We ﬁrst inves-
tigated the effect of Bz-423 on activated T cells in vitro. A 40
M concentration of Bz-423 induced apoptotic death in 	90%
of both CD4 and CD8 T lymphocytes stimulated with allo-
geneic dendritic cells (DC) or ConA in the presence of synge-
neic DC. Puriﬁed resting T cells were signiﬁcantly less suscep-
tible to Bz-423-induced apoptosis (data not shown). We next
examined the effect of Bz-423 in vivo utilizing a well-charac-
terized (Balb/c3B6) murine GVHD model. B6 recipient mice
were conditioned with 11 Gy total body irradiation and injected
with 5.0  106 bone marrow and 4-5.0  106 puriﬁed T cells
from either syngeneic (B6) or allogeneic (Balb/c) donors. In
order to model the administration of Bz-423 as a treatment
strategy rather than a prevention strategy, animals were not
treated for the ﬁrst seven days after BMT. Beginning 7 days
following BMT and continuing for the remainder of the exper-
iment, Bz-423 was administered i.p. at a dose of 60 mg/kg three
times weekly. As shown in the table below, treatment with
Bz-423 resulted in signiﬁcantly better day 60 survival (P 
.001) and reduced clinical GVHD scores (P  .02) among
allogeneic BMT recipients. Bz-423 also reduced GVH-associ-
ated immunodeﬁciency (P  .02) and decreased liver and gut
histopathology of GVHD (P  .01). Delay of the onset of
treatment to day 14 post-BMT also resulted in a signiﬁcant
survival beneﬁt (P  .03). These data demonstrate that Bz-423
can reverse acute GVHD and induce selective apoptosis of
alloreactive donor T cells in this model. Pro-apoptotic benzo-
diazepines may provide a strategy for the treatment of acute
GVHD (Table 1).
Table 1.
Syn 
Bz
Allo 
vehicle
Allo 
Bz
P
Value1
Treatment onset:
day 7
Survival (day 60) 100% (n  9) 8% (n  13) 59% (n  19) .001
GVHD clinical
score
(day 60)2
1.5  0.2 6.5  0.0 3.1  0.4 <.02
Pathology
(day 74)3
Liver 1.3  0.6 13.7  1.5 8.3  2.5 .01
Intestine 3.0  2.0 21.3  6.0 10.0  0.8 .01
Splenic
reconstitution
(day 74)3
T cells (106) 20.6  1.8 1.4  0.02 3.6  0.4 .02
B cells (106) 41.6  12.6 2.5  0.7 21.2  15.6 .02
Treatment onset:
day 14
Survival (day 60) 100% (n  3) 20% (n  5) 71% (n  6) .03
1Calculated at the 95% conﬁdence level, Allo  vehicle vs Allo 
Bz-423; 2reported as mean clinical score  SE; 3reported as mean
value  SD.
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Inducible costimulatory molecule (ICOS), a CD28 family mem-
ber expressed on activated CD4 and CD8 T cells, plays im-
portant roles in T cell activation and effector function. Here we
studied the role of ICOS in graft-versus-host disease (GVHD)
mediated by CD4 or CD8 T cells in allogeneic bone marrow
transplantation (BMT). In comparison of wild type (WT) and
ICOS-deﬁcient T cells, we found that recipients of ICOS/
CD4 T cells exhibited signiﬁcantly less GVHD morbidity and
mortality. ICOS/ CD4 T cells had no defect in expansion,
but expressed signiﬁcantly less FasL and produced signiﬁcantly
lower levels of IFN- and TNF-
. Thus, ICOS/ CD4 T
cells were impaired in effector functions that lead to GVHD. In
contrast, recipients of ICOS/ CD8 T cells exhibited signif-
icantly enhanced GVHD morbidity and mortality. In the absence
of ICOS signaling, either using ICOS-deﬁcient donors or ICOS-
ligand deﬁcient recipients, the levels of expansion and Tc1 cyto-
kine production of CD8 T cells were signiﬁcantly increased. The
level of expansion was inversely correlated with the level of
apoptosis, suggesting that increased ability of ICOS/ CD8 T
cells to induce GVHD was resulted from the enhanced survival and
expansion of those cells. Our ﬁndings indicate that ICOS has
paradoxical effects on the regulation of alloreactive CD4 and
CD8 T cells in GVHD.
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